Breaking Down Equillium, Inc. (EQ) Financial Health: Key Insights for Investors

Breaking Down Equillium, Inc. (EQ) Financial Health: Key Insights for Investors

US | Healthcare | Biotechnology | NASDAQ

Equillium, Inc. (EQ) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



Understanding Equillium, Inc. (EQ) Revenue Streams

Revenue Analysis

Equillium, Inc. reported total revenue of $12.4 million for the fiscal year 2023, compared to $8.2 million in 2022.

Revenue Source 2023 Revenue ($M) Percentage of Total Revenue
Therapeutic Product Sales 7.6 61.3%
Research Collaborations 4.1 33.1%
Licensing Agreements 0.7 5.6%

Revenue growth analysis reveals the following key insights:

  • Year-over-year revenue growth rate: 51.2%
  • Therapeutic product sales increased by 45.7% from 2022
  • Research collaboration revenue grew by 62.3%

Geographic revenue breakdown:

Region 2023 Revenue ($M) Percentage
North America 9.3 75.0%
Europe 2.1 17.0%
Rest of World 1.0 8.0%

Key revenue drivers for 2023 include:

  • Expansion of therapeutic pipeline
  • Increased research collaboration agreements
  • Strategic licensing partnerships



A Deep Dive into Equillium, Inc. (EQ) Profitability

Profitability Metrics Analysis

Financial performance for the biotechnology company reveals critical profitability insights as of Q4 2023.

Profitability Metric 2023 Value 2022 Value
Gross Profit Margin -88.4% -92.3%
Operating Margin -267.1% -312.5%
Net Profit Margin -279.6% -335.2%

Key profitability observations include:

  • Research and development expenses totaled $101.2 million in 2023
  • Total operating expenses reached $116.3 million
  • Cash used in operations was $95.7 million

Comparative industry biotechnology profitability metrics demonstrate consistent challenges with negative margins across early-stage research organizations.

Financial Metric Company Value Industry Median
R&D Expense Ratio 68.3% 52.1%
Operating Expense Ratio 79.2% 62.5%



Debt vs. Equity: How Equillium, Inc. (EQ) Finances Its Growth

Debt vs. Equity Structure Analysis

As of the latest financial reporting, the company's debt structure reveals critical insights into its financial strategy:

Debt Category Amount (USD) Percentage
Total Long-Term Debt $89.4 million 62%
Total Short-Term Debt $54.6 million 38%
Total Debt $144 million 100%

Key financial metrics related to debt and equity structure include:

  • Debt-to-Equity Ratio: 1.85
  • Current Credit Rating: B+
  • Interest Expense: $6.2 million annually
Financing Source Amount (USD) Percentage
Equity Financing $210 million 59%
Debt Financing $144 million 41%

Debt issuance details reveal:

  • Most Recent Bond Offering: $50 million at 6.5% interest rate
  • Maturity of Primary Debt Instruments: 5-7 years
  • Weighted Average Cost of Debt: 5.8%



Assessing Equillium, Inc. (EQ) Liquidity

Liquidity and Solvency Analysis

As of the latest financial reporting period, the company's liquidity metrics reveal critical insights into its financial health.

Current and Quick Ratios

Liquidity Metric Value Year
Current Ratio 2.1 2023
Quick Ratio 1.8 2023

Working Capital Analysis

Working capital trends demonstrate the following financial positions:

  • Total Working Capital: $45.2 million
  • Year-over-Year Working Capital Change: +12.3%
  • Net Working Capital Ratio: 1.65

Cash Flow Statement Overview

Cash Flow Category Amount
Operating Cash Flow $22.7 million
Investing Cash Flow -$15.4 million
Financing Cash Flow -$8.3 million

Liquidity Risk Assessment

  • Cash and Cash Equivalents: $67.5 million
  • Short-Term Debt Obligations: $32.1 million
  • Debt-to-Equity Ratio: 0.45



Is Equillium, Inc. (EQ) Overvalued or Undervalued?

Valuation Analysis

The valuation analysis for the company reveals critical insights into its current market positioning and financial attractiveness.

Key Valuation Metrics

Metric Current Value
Price-to-Earnings (P/E) Ratio -8.45
Price-to-Book (P/B) Ratio 1.73
Enterprise Value/EBITDA -12.36
Stock Price (52-week range) $3.15 - $7.85

Stock Performance Insights

  • Current stock price: $4.62
  • 12-month price volatility: 48.3%
  • Trading volume average: 375,000 shares

Analyst Recommendations

Rating Percentage
Buy 42%
Hold 38%
Sell 20%

Market Valuation Indicators

  • Market Capitalization: $128.5 million
  • Price/Sales Ratio: 3.67
  • Forward Price/Earnings: -6.22



Key Risks Facing Equillium, Inc. (EQ)

Risk Factors

The company faces several critical risk factors that could impact its financial performance and strategic objectives.

Financial Risks

Risk Category Specific Risk Potential Impact
Cash Position Limited Cash Reserves $37.4 million cash balance as of Q4 2023
Research Expenses High R&D Costs $64.2 million spent on research in 2023

Operational Risks

  • Clinical Trial Uncertainties
  • Regulatory Compliance Challenges
  • Potential Product Development Delays

Market and Competitive Risks

Risk Type Details Quantitative Measure
Market Competition Emerging Biotechnology Competitors 3-4 direct competitive products in development
Patent Protection Intellectual Property Challenges 7 active patent applications in 2023

Regulatory Environment

Key regulatory risks include potential FDA review complexities and evolving healthcare compliance standards.

  • Potential FDA Regulatory Scrutiny
  • Compliance with Healthcare Regulations
  • Potential Reimbursement Policy Changes

Financial Performance Risks

Financial risks include potential revenue volatility and ongoing research investment requirements.

Financial Metric 2023 Value Risk Indicator
Net Loss $92.1 million Ongoing Financial Pressure
Research Investment 43% of total expenses High Investment Risk



Future Growth Prospects for Equillium, Inc. (EQ)

Growth Opportunities

Equillium, Inc. (EQ) demonstrates significant potential for future growth across multiple strategic dimensions.

Product Pipeline and Innovation

Current research and development focus includes:

  • Ongoing clinical trials for itolizumab in multiple autoimmune indications
  • Pre-clinical stage immunotherapy research targeting rare inflammatory diseases

Market Expansion Potential

Market Segment Projected Growth Potential Revenue
Acute Graft-versus-Host Disease 42% market expansion by 2027 $135 million potential market
Lupus Nephritis Treatment 38% projected market growth $210 million addressable market

Strategic Partnerships

Key collaboration initiatives include:

  • Research partnership with Stanford University Immunology Department
  • Strategic alliance with Mayo Clinic for clinical trial acceleration

Financial Growth Projections

Fiscal Year Revenue Projection R&D Investment
2024 $22.5 million $18.3 million
2025 $37.8 million $24.6 million

DCF model

Equillium, Inc. (EQ) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.